In the intricate world of neuropharmacology, the standard approach to clinical trials has long relied on a deceptively simple premise: administer a fixed dose of a drug to a diverse group of individuals, then average their outcomes to declare efficacy or failure. Yet, a provocative new study challenges this fundamental assumption, revealing that such averaging […]